$3.91
-0.39[-9.07%]
At close: Apr 25
$3.91
0[0.00%]
After Hours: 7:02PM EDT
Fate Therapeutics
(NASDAQ:FATE)Latest News for Fate Therapeutics Stock (NASDAQ:FATE)
Fate Therapeutics Stock (NASDAQ: FATE)
Categories: All
Tuesday, April 23, 2024
Monday, April 22, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Thursday, March 28, 2024
Tuesday, March 19, 2024
- Fate Therapeutics Announces Pricing Of $100M Underwritten Offering And Concurrent Private PlacementBenzinga Newsdesk - Mar 19, 2024, 8:45AM
- Evaluating Fate Therapeutics: Insights From 5 Financial AnalystsBenzinga Insights - Mar 19, 2024, 8:00AM
- HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $7 Price TargetBenzinga Newsdesk - Mar 19, 2024, 6:53AM
Tuesday, February 27, 2024
- Cracking The Code: Understanding Analyst Reviews For Fate TherapeuticsBenzinga Insights - Feb 27, 2024, 3:00PM
- Barclays Maintains Overweight on Fate Therapeutics, Raises Price Target to $10Benzinga Newsdesk - Feb 27, 2024, 9:37AM
- Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For TuesdayAvi Kapoor - Feb 27, 2024, 9:09AM
- Wedbush Maintains Neutral on Fate Therapeutics, Raises Price Target to $7Benzinga Newsdesk - Feb 27, 2024, 8:49AM
- Oppenheimer Reiterates Perform on Fate Therapeuticsto PerformBenzinga Newsdesk - Feb 27, 2024, 7:39AM
Monday, February 26, 2024
Friday, February 23, 2024
Monday, January 08, 2024
- Fate Therapeutics shares are trading higher after the company announced the initiation of enrollment for its Phase 1 clinical trial of FT825 / ONO-8250 in patients with HER2-expressing advanced solid tumors.Benzinga Newsdesk - Jan 8, 2024, 12:32PM
- Fate Therapeutics Announces Initiation Of Phase 1 Clinical Trial For FT825 / ONO-8250 In Patients With HER2-Expressing Advanced Solid TumorsBenzinga Newsdesk - Jan 8, 2024, 8:04AM
Wednesday, January 03, 2024
Tuesday, December 12, 2023
Monday, November 20, 2023
Monday, November 13, 2023
Thursday, November 09, 2023
- BMO Capital Maintains Market Perform on Fate Therapeutics, Raises Price Target to $6Benzinga Newsdesk - Nov 9, 2023, 2:12PM
- Analyst Ratings for Fate TherapeuticsBenzinga Insights - Nov 9, 2023, 11:00AM
- Wedbush Maintains Neutral on Fate Therapeutics, Lowers Price Target to $3Benzinga Newsdesk - Nov 9, 2023, 10:50AM
- Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $5Benzinga Newsdesk - Nov 9, 2023, 10:38AM
Wednesday, November 08, 2023
Thursday, October 05, 2023
Tuesday, October 03, 2023
Thursday, September 21, 2023
Friday, September 15, 2023
Friday, September 08, 2023
Thursday, September 07, 2023
Tuesday, August 22, 2023
Wednesday, August 16, 2023
Monday, August 14, 2023
Friday, August 11, 2023
Thursday, August 10, 2023
- Stocks That Hit 52-Week Lows On ThursdayBenzinga Insights - Aug 10, 2023, 1:43PM
- Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $5Benzinga Newsdesk - Aug 10, 2023, 10:25AM
- Barclays Maintains Overweight on Fate Therapeutics, Lowers Price Target to $6Benzinga Newsdesk - Aug 10, 2023, 7:25AM